anti-Ro/SSA-52 kD from patients with CTDs and QTc prolongation inhibit I Kr and prolong action potential duration by directly binding the hERG-channel protein, likely at the pore region where homology between 52-kD Ro antigen and hERG is present. 7 In addition, 52-kD Ro/SSA antigenimmunized guinea pigs showed QTc prolongation on ECG after developing high titers of anti-Ro/SSA. 7 Several studies have demonstrated that anti-Ro/SSA are the most frequent autoantibodies found in the general population with a frequency ranging from 0.5% to 2.7%. [8] [9] [10] Notably, this rate increases to ≈15% when the laboratory method used is immuno-Western blotting. 11 Anti-Ro/SSA-positive subjects, are in most cases (2/3), completely asymptomatic for autoimmune diseases (ADs), 8 particularly when anti-Ro/SSA-52-kD positivity occurs alone. 12 Nakamura et al 13 reported the case of a 42-year old woman with a marked QTc prolongation and torsades de pointes (TdP) episodes with no known predisposing factors for QTc prolongation except for high levels of anti-Ro/SSA. Interestingly, serum and purified IgG from this patient also significantly reduced I Kr . It is noteworthy that this patient was asymptomatic for AD despite the presence of anti-Ro/SSA (which were detected only because the patient was tested for these autoantibodies given the absence of other QTc prolonging conditions).
Accordingly, it seems conceivable that anti-Ro/SSA may be silently involved in a number of patients who developed "idiopathic" life-threatening QT-related arrhythmias (including drug-induced TdP) and sudden unexplained deaths. To test this hypothesis, we prospectively studied patients who experienced TdP associated with QTc prolongation with the aim of evaluating (1) the prevalence of anti-Ro/SSA positivity and (ii) the electrophysiological effects of purified IgGs from antiRo/SSA-positive patients, as assessed by I Kr inhibition.
Patients and Methods

Study Population
We prospectively enrolled (from 2008 to 2015) 25 consecutive patients who presented with TdP-associated QTc prolongation, independent of ongoing therapies and concomitant diseases, including ADs. Demographic, clinical, and laboratory characteristics of study patients, as well as ongoing treatment with QTc-prolonging medications, are detailed in Table 1 and Table I in the Data Supplement. Local ethical committee approved the study, and patients gave their informed consent in accordance with the principles of the Declaration of Helsinki.
ECG Recordings
Diagnosis of TdP was based on the presence of at least 1 episode of polymorphic ventricular arrhythmia and a rate ranging from 160 to 240 beats per minutes, associated with QTc prolongation. 14 The QTc measurement is detailed in Methods in the Data Supplement.
Anti-Ro/SSA Testing
All patients underwent a venous withdrawal to determine serum antiRo/SSA by using different methods including (1) fluoroenzyme immunoassay (FEIA) by an EliA system (Phadia, Freiburg, Germany) using recombinant 60-kD and 52-kD Ro proteins, (2) iWB analysis using a kit with human Hep-2 cells as the source of extractive 60-kD and 52-kD Ro antigens, denatured by sodium dodecyl sulfate (Marblot HEp-2; MarDx, Carlsbad, CA), and (3) line-blot immunoassay (LIA) by a kit using extractive 60-kD Ro protein purified (not denaturated) from the bovine thymus and spleen by affinity chromatography and recombinant 52-kD Ro proteins (Anti-ENA Profile Plus 1 Euroline, Euroimmun, Lübeck, Germany). Moreover, all sera were also tested for antinuclear antibodies by indirect immunofluorescence on human Hep-2000 cells (Fluorescent IgG antinuclear antibody-Ro test, Immunoconcepts, Sacramento, CA).
Purification of IgG From Patients' Sera
IgG purification is detailed in Methods in the Data Supplement.
Electrophysiological Study
Experiments were performed on HEK293 cells stably expressing the hERG channel as previously described 7 and detailed in Methods in the Data Supplement.
Western Blot Analysis
Western blot experiments were performed as described in Methods in the Data Supplement.
Enzyme-Linked Immunosorbent Assay
ELISA was used for the detection of reactivity of patients' sera with a 31-amino acid sequence peptide corresponding to the extracellular loop between S5 and S6 of the pore-forming region of the α 1 -subunit of the hERG channel (E-pore peptide). Similarly, a scrambled form of the E-pore peptide was used as an internal control. The sequences of the peptides and ELISA details are described in Methods in the Data Supplement.
Statistical Analysis
Statistical evaluation of the differences between 2 groups was performed by the 2-tail Student t test for unpaired data for continuous
WHAT IS KNOWN
• In patients with autoimmune disease, anti-Ro/SSA antibodies are responsible for a novel autoimmuneassociated long-QT syndrome by targeting the hERG potassium channel and inhibiting the related current I Kr .
• Anti-Ro/SSA are the most frequent autoantibodies found in the general population, and positive subjects are, in most cases, completely asymptomatic for autoimmune diseases, particularly when anti-Ro/ SSA-52-kD positivity occurs alone.
WHAT THE STUDY ADDS
• Circulating anti-Ro/SSA antibodies are highly prevalent in patients with torsades de pointes arrhythmia, in most cases in the absence of any history of autoimmune disease.
• Anti-Ro/SSA antibodies from torsades de pointes patients are arrhythmogenic as a result of a direct cross-reaction with the hERG potassium channel at the pore region leading to I Kr inhibition.
• Anti-Ro/SSA may represent a clinically silent novel risk factor in torsades de pointes patients: these subjects may benefit from specific anti-Ro/SSA testing even in the absence of autoimmune disease as immunomodulating therapies may be effective in shortening QTc and reducing torsades de pointes recurrence risk. 
Results
Patient Characteristics
As expected, 14 most patients in our TdP population were women (≈75%) and older than 65 years (mean age, 75.2±9.6 years; Table 1 ). Moreover, a high prevalence of recognized QTc-prolonging risk factors of acquired origin were present. The most recurrent conditions are the presence of an underlying cardiac disease (76% of the cases), QTc-prolonging medications (68%), and electrolyte imbalances (64%; hypokalemia 52%). Among drugs, amiodarone was the most frequently used (32%). In all patients in this study, only 3 patients (12%) had a history of AD, rheumatoid arthritis in 2 cases, and celiac disease in the other. No patients were affected with CTD. Notably, in all cases, >1 known QTc-prolonging factor, including electrolyte imbalances, diseases, or drugs, was simultaneously identifiable, on average, >3 (Table 1; Table I in the Data Supplement).
Autoantibody Status
Anti-Ro/SSA were present in 15 (6 men) of 25 subjects (60% of the study population). In the large majority of cases (13/15), anti-Ro/SSA reactivity in serum was selectively detected by iWB and in all cases but one, the anti-Ro/SSA-52-kD subtype reactivity was detected. In 2 patients, anti-Ro/SSA-52-kD positivity was revealed by FEIA and/or LIA. Moreover, 4 patients were positive to antinuclear antibody testing, with a titer ranging from 1:80 to 1:320 ( Table 1 in the Data Supplement). Among the patients with a history of AD, 2 of 3 were anti-Ro/SSA-52-kD positive ( Table 2; Table 1 in the Data Supplement).
By comparing patients' characteristics on the basis of autoantibody status, we did not find any significant difference between the 2 groups for mean QTc duration or prevalence of QTc-prolonging risk factors, including electrolyte imbalances, diseases, and medications. However, in anti-Ro/SSApositive subjects, the mean age and incidence of female sex were both significantly lower when compared with anti-Ro/ SSA-negative patients ( Table 2) .
Because the rate of anti-Ro/SSA-52-kD-positive subjects in our cohort was particularly high and detected in most cases with iWB only, the results of all the iWB assays performed in the previous year in our laboratory were retrospectively evaluated as an internal control. Among a total of 411 subjects who underwent iWB testing for the clinical suspicion of AD, only 14.1% were anti-Ro/SSA-52-kD positive (13.9% [52/374] women and 16.2% [6/37] men). By comparing the 2 cohorts, we obtained an odds ratio of 9.1 (95% confidence interval, 3.9-21.3; 2-sided Fisher exact test, P<0.0001), indicating an ≈9-fold higher probability of having anti-Ro/SSA-52-kD positivity in the presence rather than in the absence of TdP. *Diseases recognized to be a risk factor for QTc prolongation.
14-20 †Electrolyte imbalances, diseases, and QTc-prolonging medications.
To further confirm these findings, 25 patients matched for age, sex, and concomitant diseases but without QTc prolongation or history of TdP (Table II in the Data Supplement) were prospectively enrolled as an additional control group in which anti-Ro/SSA testing with FEIA, LIA, and iWB was performed. In these subjects, anti-Ro/SSA positivity was found in 4 patients (16%), and in all cases, the anti-Ro/SSA-52-kD subtype was detected by iWB only. Again, a similar and statistically significant difference in the incidence of anti-Ro/SSA positivity between the 2 cohorts was demonstrated (odds ratio, 7.9; 95% CI, 2.1-29.9; 2-sided Fisher exact test, P=0.0031).
Anti-Ro/SSA-Positive IgGs Inhibits I Kr
To assess whether the autoantibodies functionally interact with the hERG channel, the effect of purified anti-Ro/ SSA-positive IgGs from patient number 6 was tested on I Kr .
This patient was not on any medication known to affect QT interval and had normal electrolytes (Table I in the Data Supplement). Figure 1A shows the ECG from patient 6 in a sinus rhythm (a) with a QTc=620 ms and during a TdP arrhythmia (b). Anti-Ro/SSA-positive IgG (75 μg/mL) inhibited both I Kr peak and tail currents ( Figure 1B-1F ). Selected current traces are shown before ( Figure 1B ) and after the application of anti-Ro/SSA-positive IgG (Figure 1C) . The I-V relationships for I Kr peak and tail densities before and after the application of anti-Ro/SSA-positive IgGs are shown in Figure 1D (n=6) and Figure 1E ( Figure 1G shows the voltage protocol used to record I Kr . The inhibition of I Kr was time dependent and partially reversible ( Figure 2 ). Additional anti-Ro/SSA-positive IgGs from another 7 patients (numbers 1, 2, 3, 5, 9, 11, and 15) significantly (P<0.001; n=6 each) inhibited I Kr peak (Figure 3A ) and tail densities ( Figure 3B ).
Anti-Ro/SSA-Negative IgGs Did Not Affect I Kr
The above inhibitory effect of I Kr was not observed with purified anti-Ro/SSA negative IgG from patient 16 ( Figure 4 ). This patient was not on any medication known to affect QT interval but had abnormal electrolytes (Table I in the Data Supplement). Figure 4A shows the ECG from this patient exhibiting a QTc=730 ms. Selected I Kr traces before ( Figure 4B ) and after ( Figure 4C ) the application of anti-Ro/SSA-negative IgG are shown. Figure 4D and 4E show I-V relationships of I Kr peak and tail densities before and after the application of anti-Ro/SSA-negative IgG (n=6), respectively. I Kr peak densities before and after the application of anti-Ro/SSA-negative IgG at −10 mV were 41.7±5.7 versus 38.1±5.4 pA/pF (n=6; P=0.37), and I Kr tail densities were 75.3±6.5 versus 69.9±7.2 pA/pF (n=6; P=0.27). Similarly, IgG from additional 5 antiRo/SSA-negative patients (numbers 17, 18, 19, 20, and 21) had no significant effect on I Kr peak ( Figure 5A ) and tail densities ( Figure 5B ).
Anti-Ro/SSA-Positive but Not Anti-Ro-Negative IgG Cross-React With hERG Channels
To test whether the inhibition of I Kr by anti-Ro/SSA-positive IgG is because of a direct interaction with the hERG-channel protein, Western blot experiments were performed using proteins from HEK293 cells stably expressing hERG channels (n=4) and untransfected HEK293 cells (negative control; n=4). Figure 6A shows that anti-Ro/SSA-positive IgG from patients 6 and 3 did not recognize any bands in untransfected HEK293 cells (lanes 1 and 3) but recognized 2 bands at ≈155 and 135 kDa in transfected HEK293 cells (lanes 2 and 4) corresponding to the glycosylated and endoplasmic reticulumretained hERG channel consistent with previous reports. 7, 21, 22 Figure 6B shows no bands when anti-Ro/SSA-negative IgG from patients numbers 16 and 18 was used in both untransfected HEK293 cells (lanes 1 and 3) and transfected HEK293 cells expressing hERG channels (lanes 2 and 4) . Because of the previously demonstrated 7 homology between 52-kD Ro protein (aa302-aa321) and hERG α 1 -subunit (aa574-aa598) at the pore region, we tested the reactivity of patients' sera with the E-pore peptide and its scrambled form. Sera of each patient were tested in triplicates. Figure 7A shows that anti-Ro/SSA-positive sera (n=15) showed significant reactivity to the E-pore peptide compared with the scrambled peptide (n=15) and with anti-Ro/SSA-negative sera (n=10). The average reactivity reading was 1.16±0.45 optical density in anti-Ro/SSA-positive sera versus 0.25±0.13 O.D (P<0.001) in the scrambled peptide and 0.21±0.13 optical density in anti-Ro/SSA-negative sera (P<0.001). Peptide competition experiments were performed using the E-pore peptide to neutralize the anti-Ro/SSA-positive IgG. Figure 7B shows that anti-Ro/SSA-positive IgG preincubated with the E-pore peptide resulted in a lighter band (lane 1) compared with the anti-Ro/SSA-positive IgG alone (lane 2) suggesting that the E-pore peptide bound to the anti-Ro/SSA-positive IgG. Figure 7C shows the relative hERG band densities with anti-SSA/Ro-positive IgG alone and with the preincubated E-pore peptide from a total of 4 experiments. In the presence of the E-pore peptide, the hERG band density was reduced by 65% (P<0.001).
Discussion
The main findings of this study are as follows: (1) in unselected patients with TdP, anti-Ro/SSA-52-kD positivity is highly prevalent (60% of cases); (2) in these patients, iWB is the most sensitive laboratory method to reveal the presence of circulating autoantibodies and in most cases in the absence of any history of AD; (3) purified IgGs from anti-Ro/SSApositive but not anti-Ro/SSA-negative patients presenting with TdP inhibited I Kr by direct binding to the hERG channel; (4) sera from patients anti-Ro/SSA positive exhibited reactivity to the E-pore peptide corresponding to the hERG-channel pore region. Altogether, these findings suggest that anti-Ro/ SSA may represent a clinically silent novel risk factor for TdP development as a result of an autoimmune-mediated interference with ventricular repolarization. TdP is a peculiar polymorphic ventricular tachycardia that occurs in patients with acquired and congenital long-QT syndrome (LQTS). 23 It is life threatening as it can degenerate into ventricular fibrillation and cause sudden cardiac death. Although there is no threshold of QTc prolongation at which TdP is certain to occur, the risk of TdP gradually increases as the QTc prolongs, with an ≈5% to 7% exponential increase in risk for each 10-ms prolongation of QTc. 14 Accordingly, TdP usually develops in patients with a markedly prolonged QTc, a condition in most cases requiring the simultaneous presence of multiple QTc-prolonging factors, congenital and/or acquired, that act synergistically to impair ion channels contributing to the ventricular repolarization process. 14, 23 Among these currents, a particularly relevant role is played by I Kr , conducted by the hERG-K channel whose inhibition represents the most frequently underlying molecular mechanism for LQTS and TdP, including both acquired (drugs 15 and hypokalemia 24 ) and congenital ion channel defect in LQTS2 form. 14 Mounting evidence indicates that the hERG-channel is also a specific molecular target for anti-Ro/SSA, thereby responsible for a novel form of acquired LQTS mediated by an autoimmune origin. 7, 13 Although anti-Ro/SSA-positive CTD patients frequently display QTc prolongation and complex ventricular arrhythmias, 4, 6, 25 anti-Ro/SSA are also silently present in a significant proportion of asymptomatic subjects of the general population. [8] [9] [10] [11] [12] An emblematic case of an anti-Ro/ SSA-associated TdP in an apparently healthy young woman has been recently reported in which clear evidence of a direct mechanistic link between circulating anti-Ro/SSA and QTc prolongation was provided. 13 This raises the distinct possibility that anti-Ro/SSA may represent a previously unrecognized risk factor involved in patients developing TdP. The results of this study support this view point. Indeed, we demonstrated the presence of circulating anti-Ro/SSA in 60% of TdP patients. It should be noted that, although relatively small, our study group nevertheless represents the incidence of standard risk factors usually found in the general TdP population. 14 The majority of patients usually exhibit >1 risk factor 14 (≈3.5 on average in our sample). In this regard, it is striking to note that anti-Ro/SSA positivity is the most common QTc-prolonging risk factor demonstrable, even more than the most frequently occurring classic single risk factor, that is, hypokalemia. Compared with anti-Ro/SSAnegative patients, anti-Ro/SSA-positive subjects displayed similar characteristics for mean QTc prolongation and type and mean number of standard risk factors, including electrolyte imbalances, diseases, or medications. However, anti-Ro/ SSA-positive patients were significantly younger and less frequently women when compared with anti-Ro/SSA-negative subjects. Because both advanced age and female sex per se represent 2 additional well-defined TdP risk factors in the general population, 14 this finding suggests that in anti-Ro/ SSA-positive patients, the total load of classical risk factors is actually lower than that in anti-Ro/SSA-negative subjects, with anti-Ro/SSA representing the concealed factor balancing this difference.
The demonstration that in the large majority of cases, the specific autoantibody subtype present was the anti-Ro/SSA-52 kD even in the absence of any clinical manifestation of AD, is another important result emerging from this study. This finding is in agreement with recent clinical and experimental data indicating the anti-Ro/SSA-52 kD as the specific subtype responsible for the electrophysiological effects on the ventricular repolarization. Indeed, purified anti-Ro/SSA-52 kD from CTD patients with QTc prolongation significantly inhibited I Kr in HEK293 cells stably expressing the hERG channel, and 52-kD Ro/SSA antigen-immunized guinea pigs showed QTc prolongation on the surface ECG after developing high titers of anti-Ro/SSA. 7 In CTD patients, a direct correlation has been demonstrated between anti-Ro/SSA levels and QTc prolongation but for the anti-Ro/SSA-52-kD subtype only. 26 These findings are consistent with the recent evidence obtained from linear homology analysis demonstrating homology between 52-kD Ro protein (aa302-aa321) and hERG-channel protein at the pore region (aa574-aa598). 7 This homology may account for anti-Ro/SSA off target binding to the hERG channel at this epitope mimic. The data from Figure 7 demonstrating high reactivity of anti-Ro/SSA-positive sera to the E-pore region of the hERG channel compared with anti-Ro/SSA-negative sera or to the scrambled E-pore peptide lands further support to the autoantibody interaction with the hERG channel at the pore region.
The fact that iWB analysis was the most sensitive method to detect the presence of anti-Ro/SSA-52-kD antibodies is in agreement with previous studies performed in different clinical settings. 11, 27 The reasons of these different results are not clear. The different antigen type and laboratory procedure used could make iWB more effective in revealing anti-Ro/ SSA-52 kD, particularly the specific autoantibody subfraction with the highest arrhythmogenic potential. In particular, because iWB uses the native 52-kD Ro protein (extracted by the Hep-2 cells) as an antigen unlike FEIA and LIA, which use the 52-kD Ro recombinant protein, it is plausible that only the native 52-kD Ro protein has the epitopes with the fine characteristics required to reveal the specific subfraction of anti-Ro/SSA-52 kD with pathogenic potential for the heart (ie, those able to cross-react with hERG channels). This is consistent with recent data demonstrating that many anti-Ro/SSA-52-kD FEIA-negative CTD patients with QTc prolongation actually tested positive for this antibody when assessed by iWB. 26 The significance of these findings is further confirmed by the evidence provided here that in TdP patients, the prevalence of anti-Ro/SSA-52-kD positivity as assessed by iWB was ≈4-times higher when compared with an internal reference population of >400 subjects seen at our rheumatologic clinic (60% versus 14%), as well as with a control group of 25 patients matched for age, sex, and concomitant diseases but without QTc prolongation or history of TdP, prospectively enrolled in our internal medicine ward (60% versus 16%). Notably, overlapping results have been reported by Metsküla et al 11 who found a 15% iWB positivity for anti-Ro/SSA by testing sera from 200 subjects, randomly selected from a general population sample. Further support for our data is from this study where LIA and ELISA were both markedly less sensitive than iWB, testing positive for anti-Ro/SSA in only 3.5% and 0.5% of cases, respectively. The findings from this study per se represent a validation of the iWB results as in the sera of these patients, circulating anti-Ro/SSA-52-kD antibodies are actually present (specifically the subfraction with QTc-prolonging potential) despite FEIA and LIA were negative. These findings, together with the evidence that the majority of our anti-Ro/SSA-52-kDpositive patients were clinically silent for AD, emphasize the concept that in most cases, only a specific anti-Ro/SSA testing (particularly iWB) may reveal the presence of these autoantibodies as a concurring risk factor accounting for QTc prolongation in TdP patients.
In our recent study mentioned above, 7 unequivocal experimental evidence established that anti-Ro/SSA-52 kD are able to prolong cardiomyocyte action potential and QTc through a direct cross-reaction with the hERG-channel protein. In particular, purified IgGs from sera of anti-Ro/ SSA-positive CTD patients with QTc prolongation directly bind the hERG channel and significantly inhibit I Kr . This inhibitory effect was reproduced using affinity-purified anti-Ro/SSA-52 kD. 7 It is important to note that the use of purified IgGs to perform the electrophysiology investigations ruled out the possible influence of other concomitant QTc-prolonging factors, such as drugs or electrolyte imbalances on I Kr , and pinpoint to an antibody-mediated mechanism (more particularly anti-Ro/SSA-52 kD mediated, as also indicated by our previous study 7 ). Altogether, these findings strongly support the observation that in positive TdP patients, anti-Ro/SSA-52 kD contributes synergistically with other classical risk factors concomitantly present to induce further QTc prolongation as a result of a specific electrophysiological interference with ventricular repolarization.
The potential limitations of this study include the relative small sample size and the lack of a genetic testing for concomitant LQTS-associated mutations. However, it should be underlined that TdP is an uncommon event, maybe also because it is not easily documented for the high propensity of this arrhythmia to rapidly degenerate to ventricular fibrillation and cardiac arrest. Moreover, although genetic characterization would have been useful for a more accurate definition of the total load of risk factors in the single patient (case series A B C Figure 7 . Reactivity of patients' sera with the E-loop peptide. The reactivity of patients' sera with a 31-amino acid sequence peptide corresponding to the extracellular loop between segment S5 and segment S6 of the pore-forming region of the α 1 -subunit of the hERG channel (E-pore peptide) and its corresponding scrambled peptide was assessed by ELISA. A, ELISA readings, in triplicates, illustrate reactivity to E-pore peptide (left) and scrambled peptide (right) to anti-Ro/SSA-positive patients' sera. Right, Anti-Ro/SSAnegative sera reactivity to the E-pore peptide. B, Western blots were performed using proteins from transfected HEK293 cells with hERG channels probed with purified anti-Ro/SSA-positive IgGs from patient number 4, preincubation with the E-pore peptide (lane 1) and without the E-pore peptide (lane 2). C, Relative hERG-channel bands density from 4 experiments. * indicates statistical significance at P<0.001.
identified subclinical congenital LQTS in 5%-20% of cases of drug-induced TdP 14 ), we anticipate that the presence of anti-Ro/SSA and genetic mutations along with other classical acquired risk factors will together predispose to TdP. In particular, because anti-Ro/SSA-associated QTc prolongation is due to a specific interference with hERG, it is conceivable that subjects carrying loss-of-function mutations/polymorphisms in genes encoding for hERG or other proteins regulating hERG channel function could be particularly susceptible to develop TdP in the presence of these autoantibodies. Intriguingly, in the above cited case by Nakamura et al, 13 the anti-Ro/SSApositive patient who developed TdP also tested positive for the D85N polymorphism in the KCNE1 gene. This polymorphism results in a defective expression of the MinK protein, which represents the β-subunit of voltage-gated channel conducting the slowly activating component of the delayed rectifier K current, I Ks , but it is also a key regulator of I Kr by forming a stable complex with hERG. 28 Accordingly, electrophysiological studies demonstrated that the D85N variant of KCNE1 either homozygously or heterozygously expressed in experimental cell systems significantly reduces I Kr from ≈30 to >80%. 29, 30 In conclusion, our data, for the first time, provide evidence that anti-Ro/SSA-52 kD may represent a novel, silent risk factor in patients developing TdP. These findings support the recommendation to translate into the clinical practice that patients with QTc prolongation and TdP may benefit from specific anti-Ro/SSA testing even in the absence of clinical signs of AD. The anti-Ro/SSA-mediated pathogenic activity on the ventricular repolarization seems to be related to a functional and potentially reversible electrophysiological interference with hERG-channel function. As such, immunomodulating therapies, including plasmapheresis and immunoadsorption, may be effective in shortening QTc and reducing the risk of TdP recurrence in these patients by decreasing autoantibody synthesis and/or preventing epitope binding. This view is supported by recent data from single-case reports demonstrating the effectiveness of immunosuppressive therapy in reversing QTc prolongation and other anti-Ro/SSA-associated electrocardiographic abnormalities in adults 4, [31] [32] [33] and may open novel avenues in antiarrhythmic therapy.
